Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood

The Lancet

Volumn 371, Issue 9631, 2008, Pages 2201-2212

  Feldman, Brian M ^a   Rider, Lisa G ^b   Reed, Ann M ^c   Pachman, Lauren M ^d,e  

^a Health Policy Management and Evaluation   (Canada)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c Mayo Clinic   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e CHILDREN S MEMORIAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; HLA B8 ANTIGEN; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTRACTURE; DENDRITIC CELL; DERMATOMYOSITIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; HAPLOTYPE; HEREDITY; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOGENICITY; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; MORBIDITY; MUSCLE WEAKNESS; MYOSITIS; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SKIN DISEASE; UPREGULATION;

EID: 45949111522     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60955-1     Document Type: Review

References (138)

1. Rider L., and Miller F. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 23 (1997) 619-655
2. Rider L. The heterogeneity of juvenile myositis. Autoimmun Rev 6 (2007) 241-247
3. Love L., Leff R., Fraser D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70 (1991) 360-374
4. Dalakas M., and Hohlfeld R. Polymyositis and dermatomyositis. Lancet 362 (2003) 971-982
5. Mendez E., Lipton R., Ramsey-Goldman R., et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49 (2003) 300-305
6. Symmons D., Sills J., and Davis S. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 34 (1995) 732-736
7. Pachman L., Lipton R., Ramsey-Goldman R., et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 53 (2005) 166-172
8. Pachman L., Hayford J., Chung A., et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 25 (1998) 1198-1204
9. Cooper G., Miller F., and Pandey J. The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect 107 suppl 5 (1999) 693-700
10. Pachman L., Jonasson O., Cannon R., and Friedman J. Increased frequency of HLA-B8 in juvenile dermatomyositis. Lancet 2 (1977) 1238
11. Reed A., Pachman L., and Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Human Immunol 32 (1991) 235-240
12. Mamyrova G., O'Hanlon T., Monroe J., et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 54 (2006) 3979-3987
13. Pachman L., Liotta-Davis M., Hong D., et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43 (2000) 2368-2377
14. Rider L., Artlett C., Foster C., et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol 121 (2000) 47-52
15. Christensen M., Pachman L., Schneiderman R., Patel D., and Friedman J. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum 29 (1986) 1365-1370
16. Vegosen L., Weinberg C., O'Hanlon T., Targoff I., Miller F., and Rider L. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum 56 (2007) 2719-2728
17. Pachman L., Hayford J., Hochberg M., et al. New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis. Arthritis Rheum 40 (1997) 1526-1533
18. Koch M., Brody J., and Gillespie M. Childhood polymyositis: a case-control study. Am J Epidemiol 104 (1976) 627-631
19. Massa M., Costouros N., Mazzoli F., et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum 46 (2002) 3015-3025
20. Bowles N., Dubowitz V., Sewry C., and Archard L. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet 1 (1987) 1004-1007
21. Topi G., D'Alessandro L., Catricala C., and Zardi O. Dermatomyositis-like syndrome due to toxoplasma. Br J Dermatol 101 (1979) 589-591
22. Mamyrova G., Rider L., Haagenson L., Wong S., and Brown K. Parvovirus B19 and onset of juvenile dermatomyositis. JAMA 294 (2005) 2170-2171
23. Pachman L., Litt D., Rowley A., et al. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. Arthritis Rheum 38 (1995) 1513-1518
24. Reed A., and Ytterberg S. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28 (2002) 891-916
25. Banker B., and Victor M. Dermatomyositis (systemic angiopathy) of childhood. Medicine 45 (1966) 261-289
26. Wedderburn L., Varsani H., Li C., et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with JDM, for potential use in clinical trials. Arthritis Rheum 57 (2007) 1192-1201
27. Miles L., Bove K., Lovell D., et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 57 (2007) 1183-1191
28. Tezak Z., Hoffman E., Lutz J., et al. Gene expression profiling in DQA1*0501 children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 168 (2002) 4154-4163
29. Baechler E., Bauer J., Slattery C., et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13 (2007) 59-68
30. O'Connor K., Abbott K., Sabin B., Kuroda M., and Pachman L. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 120 (2006) 319-325
31. Li C., Varsani H., Holton J., Gao B., Woo P., and Wedderburn L. MHC class I overexpression on muscles in early juvenile dermatomyositis. J Rheum 31 (2004) 605-609
32. Englund P., Nennesmo I., Klareskog L., and Lundberg I. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 46 (2002) 1044-1055
33. Dorph C., Englund P., Nennesmo I., and Lundberg I. Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis. Ann Rheum Dis 65 (2006) 1565-1571
34. Nagaraju K., Casciola-Rosen L., Lundberg I., et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 52 (2005) 1824-1835
35. Sugiura T., Kawaguchi Y., Harigai M., et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 164 (2000) 6593-6600
36. de Padilla C.L., Vallejo A., McNallan K., et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 56 (2007) 1658-1668
37. Caproni M., Torchia D., Cardinali C., et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol 151 (2004) 784-791
38. Zhao Y.-D., Fedczyna T., McVicker V., Caliendo J., Li H., and Pachman L. Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease. Clin Immunol 152 (2007) 165-172
39. Sallum A., Kiss M., Silva C., et al. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev 5 (2006) 93-100
40. Artlett C., Ramos R., Jiminez S., Patterson K., Miller F., and Rider L. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet 356 (2000) 2155-2156
41. Reed A., Picornell Y., Harwood A., and Kredich D. Chimerism in children with juvenile dermatomyositis. Lancet 356 (2000) 2156-2157
42. Reed A., McNallan K., Wettstein P., Vehe R., and Ober C. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis?. J Immunol 172 (2004) 5041-5046
43. Nirmalananthan N., Holton J., and Hanna M. Is it really myositis? A consideration of the differential diagnosis. Curr Opin Rheumatol 16 (2004) 684-691
44. Compeyrot-Lacassagne S., and Feldman B. Inflammatory myopathies in children. Pediatr Clin North Am 52 (2005) 493-520
45. Bohan A., and Peter J. Polymyositis and dermatomyositis (first of two parts). New Engl J Med 292 (1975) 344-347
46. Bohan A., and Peter J. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 (1975) 403-407
47. Brown V., Pilkington C., Feldman B., Davidson J., and Network for Juvenile Dermatomyositis PRES. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology 45 (2006) 990-993
48. McCann L., Juggins A., Maillard S., et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 years. Rheumatology 45 (2006) 1255-1260
49. Smith R., Sundberg J., Shamiyah E., Dyer A., and Pachman L. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 31 (2004) 1644-1649
50. Ingegnoli F., Zeni S., Gerloni V., and Fantini F. Capillaroscopic observations in childhood rheumatic diseases and healthy controls. Clin Exp Rheumatol 23 (2005) 905-911
51. Dolezalova P., Young S., Bacon P., and Southwood T. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis 62 (2003) 444-449
52. Sontheimer R. A portable digital microphotography unit for rapid documentation of periungual nailfold capillary changes in autoimmune connective tissue diseases. J Rheumatol 31 (2004) 539-544
53. Ramanan A., and Feldman B. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28 (2002) 833-857
54. Constantin T., Ponyi A., Orban I., et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary: clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity 39 (2006) 223-232
55. Kobayashi S., Higuchi K., Tamaki H., et al. Characteristics of juvenile dermatomyositis in Japan. Acta Paediatr Jpn 39 (1997) 257-262
56. Pachman L. Juvenile dermatomyositis. Pathophysiology and disease expression. Pediatr Clin North Am 42 (1995) 1071-1098
57. Huber A., Lang B., LeBlanc C., et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43 (2000) 541-549
58. Rider L. Calcinosis in JDM: pathogenesis and current therapies. Pediatr Rheumatol Online J 1 (2003) 119-133
59. Blane C., White S., Braunstein E., Bowyer S., and Sullivan D. Patterns of calcification in childhood dermatomyositis. Am J Roentgenol 142 (1984) 397-400
60. Moore E., Cohen F., Douglas S., and Gutta V. Staphylococcal infections in childhood dermatomyositis: association with the development of calcinosis, raised IgE concentrations and granulocyte chemotactic defect. Ann Rheum Dis 51 (1992) 378-383
61. Pachman L., Veis A., Stock S., et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum 54 (2006) 3345-3350
62. Bowyer S., Blane C., Sullivan D., and Cassidy J. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103 (1983) 882-888
63. Crowe W., Bove K., Levinson J., and Hilton P. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 25 (1982) 126-139
64. Spencer C., Hanson V., Singsen B., Bernstein B., Kornreich H., and King K. Course of treated juvenile dermatomyositis. J Pediatr 105 (1984) 399-408
65. Rouster-Stevens K., Gursahaney A., Ngai K.-L., Daru J., and Pachman L. Pharmacokinetic study of oral prednisolone compared with intravenous methyl-prednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 58 (2008) 222-226
66. Stefanski J., and Shetty A. Abdominal pain in a girl with juvenile dermatomyositis. Clin Pediatr 37 (1998) 561-563
67. Braunstein E., and White S. Pneumatosis intestinalis in dermatomyositis. Br J Radiol 53 (1980) 1011-1012
68. Rider L. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28 (2002) 935-977
69. Mamyrova G., Kleiner D., James-Newton L., Shaham B., Miller F., and Rider L. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis Rheum 57 (2007) 881-884
70. Mitchell J., Dennis G., and Rider L. Juvenile dermatomyositis presenting with anasarca: a possible indicator of severe disease activity. J Pediatr 138 (2001) 942-945
71. de Souza Neves F., Shinjo S., Carvalho J., Levy-Neto M., and Borges C. Spontaneous pneumomediastinum and dermatomyositis may be a not so rare association: report of a case and review of the literature. Clin Rheumatol 26 (2007) 105-107
72. Huemer C., Kitson H., Malleson P., et al. Lipodystrophy in patients with juvenile dermatomyositis: evaluation of clinical and metabolic abnormalities. J Rheumatol 28 (2001) 610-615
73. Verma S., Singh S., Bhalla A., and Khullar M. Study of subcutaneous fat in children with juvenile dermatomyositis. Arthritis Rheum 55 (2006) 564-568
74. Pope E., Janson A., Khambalia A., and Feldman B. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol 55 (2006) 947-950
75. Hanissian A., Masi A., Pitner S., Cape C., and Medsger Jr. T. Polymyositis and dermatomyositis in children: an epidemiologic and clinical comparative analysis. J Rheumatol 9 (1982) 390-394
76. Plamondon S., and Dent P. Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. J Rheumatol 27 (2000) 2031-2034
77. el-Azhary R., and Pakzad S. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol 46 (2002) 560-565
78. Rivas E., Gomez-Arnaiz M., Ricoy J., et al. Macrophagic myofasciitis in childhood: a controversial entity. Pediatr Neurol 33 (2005) 350-356
79. Gruis K., Teener J., and Blaivas M. Pediatric macrophagic myofasciitis associated with motor delay. Clin Neuropathol 25 (2006) 172-179
80. Krahn M., de Munain A.L., Streichenberger N., et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 59 (2006) 905-911
81. Pegoraro E., Mancias P., Swerdlow S., et al. Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol 40 (1996) 782-791
82. Sordet C., Goetz J., and Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 73 (2006) 646-654
83. O'Hanlon T., Carrick D., Targoff I., et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 85 (2006) 111-127
84. Targoff I., Mamyrova G., Trieu E., et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54 (2006) 3682-3689
85. Chinoy H., Fertig N., Oddis C., Ollier W., and Cooper R. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66 (2007) 1345-1349
86. Kaji K., Fujimoto M., Hasegawa M., et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 46 (2007) 25-28
87. Ruperto N., Ravelli A., Pistorio A., et al., Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59 (2008) 4-13
88. Miller F., Rider L., Chung Y., et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40 (2001) 1262-1273
89. Rider L., Giannini E., Brunner H., et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50 (2004) 2281-2290
90. Oddis C., Rider L., Reed A., et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52 (2005) 2607-2615
91. Isenberg D., Allen E., Farewell V., et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 43 (2004) 49-54
92. Maillard S., Jones R., Owens C., et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 43 (2004) 603-608
93. Hernandez R., Sullivan D., Chenevert T., and Keim D. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol 161 (1993) 359-366
94. Kimball A., Summers R., Turner M., et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum 43 (2000) 1866-1873
95. Summers R., Brune A., Choyke P., et al. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. Radiology 209 (1998) 191-196
96. McCann L., Garay S., Ryan M., Harris R., Riley P., and Pilkington C. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 46 (2007) 1363-1366
97. Pachman L., Callen A., Hayford J., Chung A., Sinacore J., and Ramsey-Goldman R. Juvenile dermatomyositis (JDMS): decreased calcinosis (Ca++) with intermittant high-dose intravenous methylprednisolone (IV pulse) therapy. Arthritis Rheum 37 (1994) S429
98. Klein-Gitelman M., Waters T., and Pachman L. The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 13 (2000) 360-368
99. Fischer T., Rachelefsky G., Klein R., Paulus H., and Stiehm E. Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone. Am J Dis Child 133 (1979) 386-389
100. Miller L., Sisson B., Tucker L., DeNardo B., and Schaller J. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 35 (1992) 1143-1149
101. Al-Mayouf S., Al-Mazyed A., and Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19 (2000) 138-141
102. Ramanan A., Campbell-Webster N., Ota S., et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 52 (2005) 3570-3578
103. Reiff A., Rawlings D., Shaham B., et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 24 (1997) 2436-2443
104. Pistoia V., Buoncompagni A., Scribanis R., et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol 11 (1993) 203-208
105. Heckmatt J., Hasson N., Saunders C., et al. Cyclosporin in juvenile dermatomyositis. Lancet 1 (1989) 1063-1066
106. Pediatric Rheumatology INternational Trials Organization. Juvenile dermatomyositis trial. http://www.printo.it/project_ongoing_detail.asp?ProjectID=14 (accessed Nov 1, 2007).
107. Dalakas M., Illa I., Dambrosia J., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329 (1993) 1993-2000
108. Roifman C., Schaffer F., Wachsmuth S., et al. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 258 (1987) 513-515
109. Al-Mayouf S., Laxer R., Schneider R., Silverman E., and Feldman B. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27 (2000) 2498-2503
110. Sansome A., and Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis: four year review of nine cases. Arch Dis Child 72 (1995) 25-28
111. Lang B., Laxer R., Murphy G., Silverman E., and Roifman C. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 91 (1991) 169-172
112. Olson N., and Lindsley C. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 16 (1989) 1545-1547
113. Nalda A., Caballero C., Guimeral C., Rom M., and Garcia P. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. [Spanish]. Med Clin 127 (2006) 697-701
114. Bunch T. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 24 (1981) 45-48
115. Edge J., Outland J., Dempsey J., and Callen J. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 142 (2006) 65-69
116. Riley P., Maillard S., Wedderburn L., Woo P., Murray K., and Pilkington C. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology 43 (2004) 491-496
117. Iannone F., Scioscia C., Falappone P., et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33 (2006) 1802-1804
118. Hengstman G., van den Hoogen F., Barrera P., et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50 (2003) 10-15
119. Levine T. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52 (2005) 601-607
120. Noss E., Hausner-Sypek D., and Weinblatt M. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33 (2006) 1021-1026
121. Cooper M., Willingham D., Brown D., French A., Shih F., and White A. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 56 (2007) 3107-3111
122. Oddis C., and Reed A. Rituximab in myositis (RIM) study. http://www.edc.gsph.pitt.edu/rimstudy/ (accessed Nov 1, 2007).
123. Danko K., Ponyi A., Constantin T., Borgulya G., and Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 83 (2004) 35-42
124. Hollar C., and Jorizzo J. Topical tacrolimus 0·1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 15 (2004) 35-39
125. Hicks J., Drinkard B., Summers R., and Rider L. Decreased aerobic capacity in children with juvenile dermatomyositis. Arthritis Rheum 47 (2002) 118-123
126. Alexanderson H., Dastmalchi M., Esbjornsson-Liljedahl M., Opava C., and Lundberg I. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 57 (2007) 768-777
127. Maillard S., Jones R., Owens C., et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 53 (2005) 558-564
128. Alsufyani K., Ortiz-Alvarez O., Cabral D., et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 32 (2005) 729-733
129. Rouster-Stevens K., Langman C., Price H., et al. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum 56 (2007) 977-983
130. Feldman B., and Giannini E. Where's the evidence? Putting clinical science into pediatric rheumatology. J Rheumatol 23 (1996) 1502-1504
131. Sullivan D., Cassidy J., and Petty R. Dermatomyositis in the pediatric patient. Arthritis Rheum 20 2 suppl (1977) 327-331
132. Miller III J. Late progression in dermatomyositis in childhood. J Pediatr 83 (1973) 543-548
133. Miller III J., and Koehler J. Persistance of activity in dermatomyositis of childhood. Arthritis Rheum 20 2 suppl (1977) 332-337
134. Chalmers A., Sayson R., and Walters K. Juvenile dermatomyositis: medical, social and economic status in adulthood. Can Med Assoc J 126 (1982) 31-33
135. Christen-Zäch S., Seshadri R., Sundberg J., Paller A., and Pachman L. Pathological nailfold capillaroscopy changes in juvenile dermatomyositis: association with duration of untreated disease, skin involvement over 36 months and a non-unicyclic disease course. Arthritis Rheum 58 (2008) 571-576
136. Huber A., and Feldman B. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?. Curr Rheumatol Rep 7 (2005) 441-446
137. Rider L., Pachman L., Miller F., and Bollar H. Myositis and you: a guide to dermatomyositis for patients, families, and healthcare providers (2007), The Myositis Association, Washington DC
138. Paediatric Rheumatoid INternational Organisation (PRINTO) for Paediatric Rheumatoid European Society. Information on paediatric rheumatic diseases. http://www.printo.it/pediatric-rheumatology/ (accessed Aug 26, 2007).